Last reviewed · How we verify
Prasugrel 5 mg
Prasugrel 5 mg is a Small molecule drug developed by University of Florida. It is currently FDA-approved. Also known as: Effient 5 mg.
Prasugrel 5 mg is a small molecule used to treat conditions such as Acute Coronary Syndrome, ST-Elevation Myocardial Infarction, and Coronary Artery Disease. It is compared to Clopidogrel in clinical trials, often in combination with commercially-available Aspirin, to evaluate its effectiveness in these conditions.
At a glance
| Generic name | Prasugrel 5 mg |
|---|---|
| Also known as | Effient 5 mg |
| Sponsor | University of Florida |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE) (PHASE4)
- Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion (PHASE4)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial) (PHASE3)
- Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM) (NA)
- Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2) (PHASE4)
- Percutaneous Coronary Intervention Followed by Antiplatelet Monotherapy in the Setting of Acute Coronary Syndromes (PHASE3)
- The Elderly ACS II Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prasugrel 5 mg CI brief — competitive landscape report
- Prasugrel 5 mg updates RSS · CI watch RSS
- University of Florida portfolio CI
Frequently asked questions about Prasugrel 5 mg
What is Prasugrel 5 mg?
Who makes Prasugrel 5 mg?
Is Prasugrel 5 mg also known as anything else?
What development phase is Prasugrel 5 mg in?
Related
- Manufacturer: University of Florida — full pipeline
- Also known as: Effient 5 mg
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing